Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Phase 3positiveTNX-103Positive

AI Analysis

Summary

Tenax Therapeutics announced positive Phase 3 LEVEL trial results for TNX-103 in a subgroup analysis at ESC Congress 2026, showing statistically significant 26.3-meter improvement in 6-minute walk distance compared to placebo in patients below the trial median baseline distance.

Clinical Trial Data

Phase

Phase 3

Outcome Details

In patients with baseline 6MWD below 333 meters, TNX-103 showed 26.3-meter improvement vs placebo (p = 0.0112)

Importance:7/10

Sentiment:

0.70

Phase 3 dataTNX-1036-minute walk distanceESC Congress 2026late-breaking session

Related Companies

$ALMDT.PA

Read the original article

Published by GlobeNewswire Clinical Studies on August 29, 2026 12:21 PM

Read Original